Supplementary Table S1: Treatment Protocols for Acute Lymphoblastic Leukemia in Adult Survivors (N=226)

|  |  |
| --- | --- |
| **Protocol** | **n (%)** |
| ALLR15/ALLR16^ | 4 (1.7) |
| Total therapy X\* | 7 (3.1) |
| Total therapy XI\* | 32 (14.2) |
| Total therapy XII\* | 39 (17.2) |
| Total therapy XIII\* | 111 (49.1) |
| Total therapy XIV\* | 8 (3.5) |
| Total therapy XV\* | 9 (4.0) |
| Others | 4 (1.7) |
| Non-protocol | 12(5.3) |

^ ALLR15/ALLR16 consists of etoposide administered orally as a single agent, followed by dexamethasone, vincristine, and l-asparaginase.[29]

\* The Total Therapy protocols consists of intensive systemic and intrathecal therapy but does not include cranial irradiation, irrespective of a patient's risk features. The intensity of post-remission consolidation, continuation and reinduction therapy is based on the level of minimal residual disease at the end of induction. The drugs used are prednisone, vincristine, daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, doxorubicin, cyclophosphamide, cytarabine, thioguanine, clofarabine, methotrexate, mercaptopurine, dexamethasone, etoposide and dasatinib. [1,2,30,31]